Management of drug-resistant tuberculosis

被引：206

作者：

Lange, Christoph ^{[1
,2
,3
,4
]}

Dheda, Keertan ^{[5
,6
,7
,8
]}

Chesov, Dumitru ^{[1
,9
]}

Mandalakas, Anna Maria ^{[10
,11
]}

Udwadia, Zarir ^{[12
]}

Horsburgh, C. Robert, Jr. ^{[13
,14
,15
,16
]}

机构：

[1] Res Ctr Borstel, Clin Infect Dis, D-23845 Borstel, Germany

[2] Univ Lubeck, Resp Med & Int Hlth, Lubeck, Germany

[3] German Ctr Infect Res, Clin TB Unit, Borstel, Germany

[4] Karolinska Inst, Dept Med, Stockholm, Sweden

[5] Univ Cape Town, Dept Med, Div Pulmonol, Ctr Lung Infect & Immun,Lung Inst, Cape Town, South Africa

[6] Univ Cape Town, Ctr Study Antimicrobial Resistance, Cape Town, South Africa

[7] South African Med Res Council, Cape Town, South Africa

[8] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Immunol & Infect, London, England

[9] Nicoale Testemitanu State Univ Med & Pharm, Dept Pneumol & Alergoll, Kishinev, Moldova

[10] Texas Childrens Hosp, Global TB Programme, Houston, TX 77030 USA

[11] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA

[12] Hinduja Hosp & Res Ctr, Veer Savarkar Marg, Mumbai, Maharashtra, India

[13] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA

[14] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA

[15] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA

[16] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA USA

来源：

LANCET | 2019年 / 394卷 / 10202期

基金：

英国医学研究理事会;

关键词：

CARE XPERT MTB/RIF; MYCOBACTERIUM-TUBERCULOSIS; LATENT TUBERCULOSIS; BEDAQUILINE; MULTICENTER; THERAPY; NEVIRAPINE; INFECTION; DELAMANID; CHILDREN;

D O I：

10.1016/S0140-6736(19)31882-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Drug-resistant tuberculosis is a major public health concern in many countries. Over the past decade, the number of patients infected with Mycobacterium tuberculosis resistant to the most effective drugs against tuberculosis (ie, rifampicin and isoniazid), which is called multidrug-resistant tuberculosis, has continued to increase. Globally, 4.6% of patients with tuberculosis have multidrug-resistant tuberculosis, but in some areas, like Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, this proportion exceeds 25%. Treatment for patients with multidrug-resistant tuberculosis is prolonged (ie, 9-24 months) and patients with multidrug-resistant tuberculosis have less favourable outcomes than those treated for drug-susceptible tuberculosis. Individualised multidrug-resistant tuberculosis treatment with novel (eg, bedaquiline) and repurposed (eg, linezolid, clofazimine, or meropenem) drugs and guided by genotypic and phenotypic drug susceptibility testing can improve treatment outcomes. Some clinical trials are evaluating 6-month regimens to simplify management and improve outcomes of patients with multidrug-resistant tuberculosis. Here we review optimal diagnostic and treatment strategies for patients with drug-resistant tuberculosis and their contacts.

引用

页码：953 / 966

页数：14

共 92 条

[1] Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis [J].

Ahmad, Nafees ;

Ahuja, Shama D. ;

Akkerman, Onno W. ;

Alffenaar, Jan-Willem C. ;

Anderson, Laura F. ;

Baghaei, Parvaneh ;

Bang, Didi ;

Barry, Pennan M. ;

Bastos, Mayara L. ;

Behera, Digamber ;

Benedetti, Andrea ;

Bisson, Gregory P. ;

Boeree, Martin J. ;

Bonnet, Maryline ;

Brode, Sarah K. ;

Brust, James C. M. ;

Cai, Ying ;

Caumes, Eric ;

Cegielski, J. Peter ;

Centis, Rosella ;

Chan, Pei-Chun ;

Chan, Edward D. ;

Chang, Kwok-Chiu ;

Charles, Macarthur ;

Cirule, Andra ;

Dalcolmo, Margareth Pretti ;

D'Ambrosio, Lia ;

de Vries, Gerard ;

Dheda, Keertan ;

Esmail, Aliasgar ;

Flood, Jennifer ;

Fox, Gregory J. ;

Frechet-Jachym, Mathilde ;

Fregona, Geisa ;

Gayoso, Regina ;

Gegia, Medea ;

Gler, Maria Tarcela ;

Gu, Sue ;

Guglielmetti, Lorenzo ;

Holtz, Timothy H. ;

Hughes, Jennifer ;

Isaakidis, Petros ;

Jarlsberg, Leah ;

Kempker, Russell R. ;

Keshavjee, Salmaan ;

Khan, Faiz Ahmad ;

Kipiani, Maia ;

Koenig, Serena P. ;

Koh, Won-Jung ;

Kritski, Afranio .

LANCET, 2018, 392 (10150) :821-834

[2]

ALLAN WGL, 1977, AM REV RESPIR DIS, V115, P727

[3] Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing [J].

Allix-Beguec, Caroline ;

Arandjelovic, Irena ;

Bi, Lijun ;

Beckert, Patrick ;

Bonnet, Maryline ;

Bradley, Phelim ;

Cabibbe, Andrea M. ;

Cancino-Munoz, Irving ;

Caulfield, Mark J. ;

Chaiprasert, Angkana ;

Cirillo, Daniela M. ;

Clifton, David ;

Comas, Inaki ;

Crook, Derrick W. ;

De Filippo, Maria R. ;

de Neeling, Han ;

Diel, Roland ;

Drobniewski, Francis A. ;

Faksri, Kiatichai ;

Farhat, Maha R. ;

Fleming, Joy ;

Fowler, Philip ;

Fowler, Tom A. ;

Gao, Qian ;

Gardy, Jennifer ;

Gascoyne-Binzi, Deborah ;

Gibertoni-Cruz, Ana-Luiza ;

Gil-Brusola, Ana ;

Golubchik, Tanya ;

Gonzalo, Ximena ;

Grandjean, Louis ;

He, Guangxue ;

Guthrie, Jennifer L. ;

Hoosdally, Sarah ;

Hunt, Martin ;

Iqbal, Zamin ;

Ismail, Nazir ;

Johnston, James ;

Khanzada, Faisal M. ;

Khor, Chiea C. ;

Kohl, Thomas A. ;

Kong, Clare ;

Lipworth, Sam ;

Liu, Qingyun ;

Maphalala, Gugu ;

Martinez, Elena ;

Mathys, Vanessa ;

Merker, Matthias ;

Miotto, Paolo ;

Mistry, Nerges .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (15) :1403-1415

[4]

[Anonymous], 2016, CASE REP OBSTET GYNE

[5]

[Anonymous], GLOB TUB REP 2018

[6]

[Anonymous], 2016, Treatment Guidelines for Drug Resistant Tuberculosis, 2016 Update

[7]

[Anonymous], 2019, HIV DRUG INT

[8]

[Anonymous], 2018, Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis

[9]

[Anonymous], 2018, INT J TUBER LUNG DIS

[10]

[Anonymous], AIDS INF DRUGS

← 1 2 3 4 5 6 7 8 9 10 →